Blockchain analytics firm Chainalysis has released a new report revealing that the annual turnover of the gray market peptide industry has breached the $100 million mark, prompting top suppliers to accelerate their adoption of Bitcoin and stablecoins as primary settlement methods. Data shows that cryptocurrency inflows into the sector totaled $32 million in the first quarter of 2026, a 159% jump compared to the previous quarter, underscoring the rapid penetration of crypto payments in this niche.
The immediate cause behind this shift lies in the strict restrictions imposed by traditional financial channels. Banks and credit card networks largely prohibit processing payments for prescription-grade compounds and unregulated substances, forcing a large number of Chinese chemical manufacturers to turn to crypto assets. Notably, high-value orders tend to favor stablecoins to shield against the price volatility risks inherent in assets like Bitcoin.
Crypto Filling the Payment Void
Chainalysis highlights that the 159% quarterly surge in crypto inflows to the gray peptide industry illustrates the essential role digital assets play in areas underserved by conventional finance. Chinese chemical manufacturers have become key drivers of this trend, increasingly using Bitcoin and stablecoins to keep global supply chains running after being cut off from traditional rails. Stablecoins, with their fiat-pegged value stability, dominate large-ticket settlements—often reaching tens or hundreds of thousands of dollars—helping both sides manage market swings effectively.